Tecentriq (atezolizumab) and Avastin (bevacizumab): Atezolizumab in combination with bevacizumab is NOT approved as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation and the benefit-risk profile does not support the use of atezolizumab plus bevacizumab in this setting